Power-law tails in probability density functions of molecular cloud column density

Power-law tails are often seen in probability density functions (PDFs) of molecular cloud column densities, and have been attributed to the effect of gravity. We show that extinction PDFs of a sample of five molecular clouds obtained at a few tenths of a parsec resolution, probing extinctions up to A$_{{\mathrm{V}}}$ $\sim$ 10 magnitudes, are very well described by lognormal functions provided that the field selection is tightly constrained to the cold, molecular zone and that noise and foreground contamination are appropriately accounted for. In general, field selections that incorporate warm, diffuse material in addition to the cold, molecular material will display apparent core+tail PDFs. The apparent tail, however, is best understood as the high extinction part of a lognormal PDF arising from the cold, molecular part of the cloud. We also describe the effects of noise and foreground/background contamination on the PDF structure, and show that these can, if not appropriately accounted for, induce spurious tails or amplify any that are truly present.Comment: Accepted for publication in MNRA

Synthetic Observations of the HI Line in SPH-Simulated Spiral Galaxies

Using the radiative transfer code Torus, we produce spectral-line cubes of the predicted HI profile from global SPH simulations of spiral galaxies. Torus grids the SPH galaxy using Adaptive Mesh Refinement, then applies a ray-tracing method to infer the HI profile along the line(s) of sight. The gridded galaxy can be observed from any direction, which enables us to model the observed HI profile for galaxies of any orientation. We can also place the observer inside the galaxy, to simulate HI observations taken from the Earth's position in the Milky Way.Comment: 4 pages, 2 figures, conference proceedings for "Panoramic Radio Astronomy: 1-2 Ghz Research on Galaxy Evolution" June 2-5, 2009 Groninge

Large-Scale Structure of the Molecular Gas in Taurus Revealed by High Linear Dynamic Range Spectral Line Mapping

We report the results of a 100 square degree survey of the Taurus Molecular Cloud region in the J = 1-0 transition of 12CO and 13CO. The image of the cloud in each velocity channel includes ~ 3 million Nyquist sampled pixels on a 20" grid. The high sensitivity and large linear dynamic range of the maps in both isotopologues reveal a very complex, highly structured cloud morphology. There are large scale correlated structures evident in 13CO emission having very fine dimensions, including filaments, cavities, and rings. The 12CO emission shows a quite different structure, with particularly complex interfaces between regions of greater and smaller column density defining the boundaries of the largest-scale cloud structures. The axes of the striations seen in the 12CO emission from relatively diffuse gas are aligned with the direction of the magnetic field. Using a column density-dependent model for the CO fractional abundance, we derive the mass of the region mapped to be 24,000 solar masses, a factor of three greater than would be obtained with canonical CO abundance restricted to the high column density regions. We determine that half the mass of the cloud is in regions having column density below 2.1x10^{21} per square cm. The distribution of young stars in the region covered is highly nonuniform, with the probability of finding a star in a pixel with a specified column density rising sharply for N(H2) = 6x10^{21} cm^{-2}. We determine a relatively low star formation efficiency (mass of young stars/mass of molecular gas), between 0.3 and 1.2 %, and an average star formation rate during the past 3 Myr of 8x10^{-5} stars yr^{-1}.Comment: 53 pages, 21 figure

A High Resolution Survey of the Galactic Plane at 408 MHz

The interstellar medium is a complex 'ecosystem' with gas constituents in the atomic, molecular, and ionized states, dust, magnetic fields, and relativistic particles. The Canadian Galactic Plane Survey has imaged these constituents with angular resolution of the order of arcminutes. This paper presents radio continuum data at 408 MHz over the area 52 degrees < longitude < 193 degrees, -6.5 degrees < latitude < 8.5 degrees, with an extension to latitude = 21 degrees in the range 97 degrees < longitude < 120 degrees, with angular resolution 2.8' x 2.8' cosec(declination). Observations were made with the Synthesis Telescope at the Dominion Radio Astrophysical Observatory as part of the Canadian Galactic Plane Survey. The calibration of the survey using existing radio source catalogs is described. The accuracy of 408-MHz flux densities from the data is 6%. Information on large structures has been incorporated into the data using the single-antenna survey of Haslam (1982). The paper presents the data, describes how it can be accessed electronically, and gives examples of applications of the data to ISM research.Comment: Accepted for publication in the Astronomical Journa

ARomatase Inhibition plus/minus Src-inhibitor SaracaTinib (AZD0530) in Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study

PURPOSE: The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast activity. We aimed to evaluate the efficacy of saracatinib addition to aromatase inhibitors (AI) in patients with hormone receptor-positive metastatic breast cancer. METHODS: This phase II multicentre double-blinded randomised trial allocated post-menopausal women to AI with either saracatinib or placebo (1:1 ratio). Patients were stratified into an "AI-sensitive/naïve" group who received anastrozole and "prior-AI" group who received exemestane. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR) and toxicity. RESULTS: 140 patients were randomised from 20 UK centres to saracatinib/AI (n = 69) or placebo/AI (n = 71). Saracatinib was not associated with an improved PFS (3.7 months v. 5.6 months placebo/AI) and did not reduce likelihood of bony progression. There was no benefit in OS or ORR. Effects were consistent in "AI-sensitive/naive" and "prior-AI" sub-groups. Saracatinib was well tolerated with dose reductions in 16% and the main side effects were gastrointestinal, hypophosphatemia and rash. CONCLUSION: Saracatinib did not improve outcomes in post-menopausal women with metastatic breast cancer. There was no observed beneficial effect on bone metastases. CRUKE/11/023, ISRCTN23804370

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received

Background The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. Objective To report outcomes according to treatment received in men in randomised and treatment choice cohorts. Design, setting, and participants This study focuses on secondary care. Men with clinically localised prostate cancer at one of nine UK centres were invited to participate in the treatment trial comparing AM, radical prostatectomy, and radiotherapy. Intervention Two cohorts included 1643 men who agreed to be randomised and 997 who declined randomisation and chose treatment. Outcome measurements and statistical analysis Analysis was carried out to assess mortality, metastasis and progression and health-related quality of life impacts on urinary, bowel, and sexual function using patient-reported outcome measures. Analysis was based on comparisons between groups defined by treatment received for both randomised and treatment choice cohorts in turn, with pooled estimates of intervention effect obtained using meta-analysis. Differences were estimated with adjustment for known prognostic factors using propensity scores. Results and limitations According to treatment received, more men receiving AM died of PCa (AM 1.85%, surgery 0.67%, radiotherapy 0.73%), whilst this difference remained consistent with chance in the randomised cohort (p = 0.08); stronger evidence was found in the exploratory analyses (randomised plus choice cohort) when AM was compared with the combined radical treatment group (p = 0.003). There was also strong evidence that metastasis (AM 5.6%, surgery 2.4%, radiotherapy 2.7%) and disease progression (AM 20.35%, surgery 5.87%, radiotherapy 6.62%) were more common in the AM group. Compared with AM, there were higher risks of sexual dysfunction (95% at 6 mo) and urinary incontinence (55% at 6 mo) after surgery, and of sexual dysfunction (88% at 6 mo) and bowel dysfunction (5% at 6 mo) after radiotherapy. The key limitations are the potential for bias when comparing groups defined by treatment received and changes in the protocol for AM during the lengthy follow-up required in trials of screen-detected PCa. Conclusions Analyses according to treatment received showed increased rates of disease-related events and lower rates of patient-reported harms in men managed by AM compared with men managed by radical treatment, and stronger evidence of greater PCa mortality in the AM group. Patient summary More than 95 out of every 100 men with low or intermediate risk localised prostate cancer do not die of prostate cancer within 10 yr, irrespective of whether treatment is by means of monitoring, surgery, or radiotherapy. Side effects on sexual and bladder function are better after active monitoring, but the risks of spreading of prostate cancer are more common